Fatal laboratory-acquired infection with an attenuated
Illinois, 2009

Morbidity and Mortality Weekly Report

60, 201-5

Citation Report

#	Article	IF	Citations
1	Plague: Infections of Companion Animals and Opportunities for Intervention. Animals, 2011, 1, 242-255.	1.0	9
2	Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. Comparative Immunology, Microbiology and Infectious Diseases, 2013, 36, 113-128.	0.7	5
3	Plague: History and contemporary analysis. Journal of Infection, 2013, 66, 18-26.	1.7	90
4	Plague Gives Surprises in the First Decade of the 21st Century in the United States and Worldwide. American Journal of Tropical Medicine and Hygiene, 2013, 89, 788-793.	0.6	97
5	Susceptibility and Response to Infection. , 2014, , .		0
6	Risks and Benefits of Gain-of-Function Experiments with Pathogens of Pandemic Potential, Such as Influenza Virus: a Call for a Science-Based Discussion. MBio, 2014, 5, e01730-14.	1.8	57
7	Development of real-time PCR assays for specific detection of hmsH, hmsF, hmsR, and irp2 located within the 102-kb pgm locus of Yersinia pestis. Molecular and Cellular Probes, 2014, 28, 288-295.	0.9	7
8	Biologically Hazardous Agents at Work and Efforts to Protect Workers' Health: A Review of Recent Reports. Safety and Health at Work, 2014, 5, 43-52.	0.3	63
9	Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages. Microbial Pathogenesis, 2015, 80, 27-38.	1.3	9
10	Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague. Vaccine Journal, 2015, 22, 1255-1268.	3.2	15
11	High-Throughput, Signature-Tagged Mutagenic Approach To Identify Novel Virulence Factors of Yersinia pestis CO92 in a Mouse Model of Infection. Infection and Immunity, 2015, 83, 2065-2081.	1.0	19
12	Risk Assessment of Biological Hazards. , 0, , 93-104.		0
13	Laboratory-Associated Infections. , 2016, , 59-92.		5
14	Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. Npj Vaccines, 2016, 1, 16020.	2.9	17
15	Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1247-1258.	1.3	75
16	Emerging technologies and bio-threats. , 2016, , 117-135.		1
17	Laboratory-acquired dengue virus infection by needlestick injury: a case report, South Korea, 2014. Annals of Occupational and Environmental Medicine, 2016, 28, 16.	0.3	17
18	Identification of New Virulence Factors and Vaccine Candidates for Yersinia pestis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 448.	1.8	23

#	Article	IF	Citations
19	Safety considerations for working with animal models involving human health hazards. Animal Models and Experimental Medicine, 2018, 1, 91-99.	1.3	3
20	Plague Vaccines. , 2018, , 762-772.e4.		0
21	Case Investigations of Infectious Diseases Occurring in Workplaces, United States, 2006â€“2015. Emerging Infectious Diseases, 2019, 25, 397-405.	2.0	32
22	Plague vaccine: recent progress and prospects. Npj Vaccines, 2019, 4, 11.	2.9	60
23	Developing a culture of safety in biomedical research training. Molecular Biology of the Cell, 2020, 31, 2409-2414.	0.9	3
24	Plague Transmission from Corpses and Carcasses. Emerging Infectious Diseases, 2021, 27, 2033-2041.	2.0	7
25	Protection Elicited by Attenuated Live Yersinia pestis Vaccine Strains against Lethal Infection with Virulent Y. pestis. Vaccines, 2021, 9, 161.	2.1	12
26	Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. MMWR Recommendations and Reports, 2021, 70, 1-27.	26.7	31
27	Yersinia Species (Including Plague). , 2015, , 2607-2618.e2.		9
28	Yersinia. , 0, , 738-751.		7
29	Viral Agents of Human Disease: Biosafety Concerns. , 0, , 187-220.		1
30	Plague Prevention and Therapy: Perspectives on Current and Future Strategies. Biomedicines, 2021, 9, 1421.	1.4	8
31	Surveillance of laboratory exposures to human pathogens and toxins: Canada 2016. Canada Communicable Disease Report, 2017, 43, 228-235.	0.6	7
32	The Acquisition and Consumption of Host Nutrients. , 2019, , 131-144.		1
34	Zika Virus Infection During Research Vaccine Development: Investigation of the Laboratory-Acquired Infection via Nanopore Whole-Genome Sequencing. Frontiers in Cellular and Infection Microbiology, 2022, 12, 819829.	1.8	1